Quarterly report pursuant to Section 13 or 15(d)

Revenue (Tables)

v3.19.2
Revenue (Tables)
 6 Months Ended
Jun. 30, 2019
Revenue from Contract with Customer [Abstract]  
Schedule of Recognized Revenues
During the three and six months ended June 30, 2019 and 2018, respectively, the Company recognized revenues as follows (in thousands):
 
Three Months Ended June 30
 
Six Months Ended June 30
 
2019
 
2018
 
2019
 
2018
Revenue from contracts with customers
$
4,934

 
$
11,224

 
$
12,468

 
$
14,668

Collaboration revenue (ASC 808)
398

 
467

 
1,409

 
1,084

Other revenues
—

 
—

 
—

 
91

Total Revenue
$
5,332

 
$
11,691

 
$
13,877

 
$
15,843


Included in the revenue from contracts with customers for the three and six months ended June 30, 2019 was $2.4 million and $6.5 million, respectively, that was included in the aggregated deferred liability balances at December 31, 2018.
During the three and six months ended June 30, 2019 and 2018, respectively, the Company recognized revenue from the following strategic partnerships and other license agreements (in thousands):
 
Three Months Ended June 30
 
Six Months Ended June 30
 
2019
 
2018
 
2019
 
2018
Seattle Genetics
$
504

 
$
2,425

 
$
1,429

 
$
2,731

AstraZeneca
3,888

 
6,390

 
9,908

 
8,937

Servier
940

 
1,419

 
2,540

 
2,627

Other
—

 
1,457

 
—

 
1,548

Total Revenue
$
5,332

 
$
11,691

 
$
13,877

 
$
15,843

Schedule of Potential Milestone Payments
Under the Company´s existing strategic partnerships, the Company could receive the following potential milestone payments (in millions):
 
Research, Development & Commercial Milestones
 
Sales Milestones
Seattle Genetics
$
769

 
$
450

AstraZeneca
1,111

 
960

Servier
984

 
892

Total potential milestone payments
$
2,864

 
$
2,302